Cancer Research and Treatment

Original Article

Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement: Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Deok-Hwan Yang, Hyeoung-Joon Kim, Jin Young Kim, Young Rok Do, Keon Uk Park, Hong Suk Song, Ki Young Kwon, Min Kyung Kim, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Hwak Kim, Sang Kyun Sohn; Cancer Res Treat. 2013;45(2):112-117. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.112

PURPOSE
We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
MATERIALS AND METHODS
A total of 567 consecutive patients with newly diagnosed DLBCL treated with rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included in the current study. All of the patients underwent a BM study at the initial staging and the clinical characteristics and prognosis of these patients with or without BM involvement were analyzed retrospectively.
RESULTS
The total cohort included 567 patients. The overall incidence of BM involvement was 8.5%. With a median follow-up duration of 33.2 months (range, 0.1 to 80.7 months) for patients who were alive at the last follow-up, the five-year overall survival (OS) and event-free survival (EFS) rate in patients without BM involvement (76.3% and 67.5%, p<0.001) was statistically higher than that in patients with BM involvement (44.3% and 40.1%, p<0.001). In multivariate analysis, among total patients, BM involvement showed a significant association with OS and EFS. In univariate and multivariate analyses, even among stage IV patients, a significant association with worse EFS was observed in the BM involvement group.
CONCLUSION
BM involvement at diagnosis affected the survival of patients with DLBCL who received RCHOP. Although use of RCHOP can result in significant improvement of the therapeutic effect of DLBCL, BM involvement is still a negative prognostic factor of DLBCL patients in the era of rituximab.

Citations

Citations to this article as recorded by

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Eri Kawata, Hitoji Uchiyama, Junya Kuroda
Diagnostics.2021; 11(9): 1724. CrossRef
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
Jeffrey W. Craig, Michael J. Mina, Jennifer L. Crombie, Ann S. LaCasce, David M. Weinstock, Geraldine S. Pinkus, Olga Pozdnyakova, Francesco Bertolini
PLOS ONE.2018; 13(7): e0199708. CrossRef
HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era
Maria Joao Baptista, Olga Garcia, Mireia Morgades, Eva Gonzalez-Barca, Pilar Miralles, Armando Lopez-Guillermo, Eugenia Abella, Miriam Moreno, Juan-Manuel Sancho, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
AIDS.2015; 29(7): 811. CrossRef
Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
José Carlos Jaime-Pérez, Carmen Magdalena Gamboa-Alonso, Alberto Vázquez-Mellado de Larracoechea, Marisol Rodríguez-Martínez, César Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer
Archives of Medical Research.2015; 46(6): 454. CrossRef

25,076 View
63 Download
4 Crossref

Case Report

A Case of Spine Origin Chondroblastoma Metastasis to Lung: Se Hoon Sohn, Sung Aee Koh, Dong Geun Kim, Sung Woo Park, Kyung Hee Lee, Min Kyoung Kim, Jun Hyuk Choi, Myung Soo Hyun; Cancer Res Treat. 2009;41(4):241-244. Published online December 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.4.241

Abstract PDF PubReader ePub

Chondroblastoma is a rare benign cartilaginous neoplasm that accounts for approximately 1% of all bone tumors and characteristically arises in the epiphysis of a long bone, particularly the humerus, tibia, and femur. Chondroblastoma can affect people of all ages. It is, however, most common in children and young adults between the ages of 10 and 20 years. Although most chondroblastomas are cured by limited surgical procedures, occasional lesions behave more aggressively and may even metastasis. In this case a young man with pulmonary metastatic chondroblastoma on spine is presented. Unlike previously published examples of metastatic chondroblastoma, these metastasis developed before any operative manipulation of the primary tumor. And primary tumor site was also unusual. The histologic characteristics of the primary, metastatic tumors were those of a conventional chondroblastoma.

Citations

Citations to this article as recorded by

A rare case of chondroblastoma of the jugular foramen: Imaging and pathological features
Kai-Jie Wang, Tian-Cheng Lin, Wei-Yuan Huang
Radiology Case Reports.2025; 20(5): 2527. CrossRef
Chondroblastoma of Thoracic Vertebrae: a Case Report and Review of the Literature
Alireza Tabibkhooei, Parisa Javadnia
Indian Journal of Surgical Oncology.2024; 15(S1): 22. CrossRef
Bone metastases from chondroblastoma: a rare pattern of metastatic disease in an adult
Jennifer Murphy, Anish Patel, Simon Hughes, Petr Rehousek, John Drake, Vaiyapuri Sumathi, Rajesh Botchu, A. Mark Davies
Skeletal Radiology.2024; 53(6): 1219. CrossRef
Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches
Ramy Samargandi, Abrar Bafail, Louis-Romée Le Nail, Julien Berhouet
Cancers.2024; 16(12): 2283. CrossRef
Clinicopathological and Prognostic Characteristics in Spinal Chondroblastomas: A Pooled Analysis of Individual Patient Data From a Single Institute and 27 Studies
Bo-Wen Zheng, Wei Huang, Fu-Sheng Liu, Tao-Lan Zhang, Xiao-Bin Wang, Jing Li, Guo-Hua Lv, Yi-Guo Yan, Ming-Xiang Zou
Global Spine Journal.2023; 13(3): 713. CrossRef
Chondroblastoma: clinicopathological analyses of 307 cases from a single institution in China and the diagnostic value of the H3F3 K36M mutant antibody
Qianqian Zhao, Juan Tang, Yanli Luo, Jin Huang, Dingjun Hu, Jinyu Zhu, Ting Jiang, Huizhen Zhang, Zhiyan Liu
Journal of Clinical Pathology.2023; 76(6): 367. CrossRef
Clinicopathological characteristics and prognostic factors in axial chondroblastomas: a retrospective analysis of 61 cases and comparison with extra-axial chondroblastomas
Bo-Wen Zheng, Bo-Yv Zheng, Hua-Qing Niu, Ming-Xiang Zou, Hai-Lin Wu, Ming Wang, Xue-Lin Li
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Pulmonary Metastases of Chondroblastoma in a Pediatric Patient: A Case Report and Review of Literature
Courtney Wing, Pankaj Watal, Monica Epelman, Juan Infante, Tushar Chandra
Cureus.2022;[Epub] CrossRef
Missed radiographic and clinical findings in a case of non-idiopathic scoliosis resulting from chondroblastoma
Navraj S. Sagoo, Edward P. Southern, Andrew G. King, Matthew W. Stark, Lori A. McBride
Spine Deformity.2021; 9(1): 297. CrossRef
Sacral chondroblastoma — a rare location, a rare pathology: A case report and review of literature
Bo-Wen Zheng, Hua-Qing Niu, Xiao-Bin Wang, Jing Li
World Journal of Clinical Cases.2021; 9(20): 5709. CrossRef
Chondroblastoma of the knee in a teenager
Maitham Alkadumi, Neil Duggal, Sukhman Kaur, Joseph Dobtsis
Radiology Case Reports.2021; 16(12): 3729. CrossRef
Pediatric Chondroblastoma and the Need for Lung Staging at Presentation
Alexandre Arkader, Amy Williams, Odion Binitie, Mihir M. Thacker, German L. Farfalli
Journal of Pediatric Orthopaedics.2020; 40(9): e894. CrossRef
Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy
David I. Suster, Pawel Kurzawa, Azfar Neyaz, Jason A. Jarzembowski, Santiago Lozano-Calderon, Kevin Raskin, Joseph Schwab, Edwin Choy, Ivan Chebib, Vikram Deshpande
American Journal of Surgical Pathology.2020; 44(12): 1581. CrossRef
Histone H3K36M mutation and trimethylation patterns in chondroblastoma
Chuanyong Lu, Daniel Ramirez, Sinchun Hwang, Achim Jungbluth, Denise Frosina, Peter Ntiamoah, John Healey, Guo Zhu, Wen Chen, Michael Klein, Meera Hameed
Histopathology.2019; 74(2): 291. CrossRef
Chondroblastoma of bone in extremities. - A single centre study of 177 cases
M.K. Laitinen, J.D. Stevenson, S. Evans, A. Abudu, V. Sumathi, L.M. Jeys, M.C. Parry
Journal of Bone Oncology.2019; : 100248. CrossRef
Clinical features, treatments and long-term follow-up outcomes of spinal chondroblastoma: report of 13 clinical cases in a single center
Qi Jia, Chao Liu, Jian Yang, Yong Ji, Haifeng Wei, Tielong Liu, Xinghai Yang, Cheng Yang, Jianru Xiao
Journal of Neuro-Oncology.2018; 140(1): 99. CrossRef
Chondroblastoma: An evaluation of the recurrences and functional outcomes following treatment
Devrim Özer, Yavuz Arıkan, Volkan Gür, Cantay Gök, Yunus Emre Akman
Acta Orthopaedica et Traumatologica Turcica.2018; 52(6): 415. CrossRef
Condroblastoma óseo
F. Sailhan, M. Bachy, B. Tomeno, V. Dumaine, A. Babinet, P. Anract
EMC - Aparato Locomotor.2014; 47(1): 1. CrossRef
Chondroblastoma of the Navicular Bone
XiaoNa Li, ZhiGang Peng, JingPin Zhao, ZeKun Zhang
Iranian Journal of Radiology.2014;[Epub] CrossRef
Douleur de l’épaule révélant un chondroblastome huméral
A. Zrig, M. Zrig, W. Mnari, H. El Mhabrech, R. Salem, A. Abid, M. Golli
Archives de Pédiatrie.2014; 21(12): 1386. CrossRef
Chondroblastoma of the Knee Treated with Resection and Osteochondral Allograft Reconstruction
Judd Fitzgerald, Cory Broehm, David Chafey, Gehron Treme
Case Reports in Orthopedics.2014; 2014: 1. CrossRef
Chondroblastoma of the Lumbar Vertebra Associated with Cauda Equina Compression
Yeap Ewe-Juan, Siow Yew-Siong, Deepak Ajit-Singh
Journal of Orthopaedics, Trauma and Rehabilitation.2013; 17(2): 99. CrossRef
A Massive Chondroblastoma in the Proximal Humerus Simulating Malignant Bone Tumors
Ichiro Tonogai, Mitsuhiko Takahashi, Hiroaki Manabe, Toshihiko Nishisho, Seiji Iwamoto, Shoichiro Takao, Seiko Kagawa, Eiji Kudo, Natsuo Yasui
Case Reports in Orthopedics.2013; 2013: 1. CrossRef

11,475 View
80 Download
23 Crossref

Original Articles

Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer: Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee; Cancer Res Treat. 2009;41(1):12-18. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.12

Abstract PDF PubReader ePub

Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m²) or cisplatin (60 mg/m²) was given over 1 hour with 5-FU (1 gm/m²) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
Chemical Physics Letters.2024; 842: 141191. CrossRef
Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
S. Shruthi, K. Bhasker Shenoy
ChemistrySelect.2024;[Epub] CrossRef
Recent Advances on Pt-Based Compounds for Theranostic Applications
Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
Molecules.2024; 29(15): 3453. CrossRef
Hallmarks of anticancer and antimicrobial activities of corroles
Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
Drug Resistance Updates.2023; : 100931. CrossRef
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef
Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
Coordination Chemistry Reviews.2022; 472: 214790. CrossRef
Metalofármacos en la terapia contra el cáncer
Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
TECNOCIENCIA Chihuahua.2022; 16(3): e1010. CrossRef
Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Dan Gibson
Journal of Inorganic Biochemistry.2021; 217: 111353. CrossRef
Monofunctional Platinum(II) Anticancer Agents
Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
Pharmaceuticals.2021; 14(2): 133. CrossRef
Pt(IV) Prodrugs with NSAIDs as Axial Ligands
Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
International Journal of Molecular Sciences.2021; 22(8): 3817. CrossRef
Multi-action Pt(IV) anticancer agents; do we understand how they work?
Dan Gibson
Journal of Inorganic Biochemistry.2019; 191: 77. CrossRef
TOXview: a novel graphical presentation of cancer treatment toxicity profiles
Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Acta Oncologica.2019; 58(8): 1138. CrossRef
Photoactivated platinum-based anticancer drugs
Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
Coordination Chemistry Reviews.2018; 376: 405. CrossRef
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
Cancer Chemotherapy and Pharmacology.2018; 81(6): 981. CrossRef
An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
Management Science.2016; 62(5): 1511. CrossRef
Platinum(iv) anticancer prodrugs – hypotheses and facts
Dan Gibson
Dalton Transactions.2016; 45(33): 12983. CrossRef
Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
Journal of Inorganic Biochemistry.2016; 162: 109. CrossRef
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
Molecular Pharmaceutics.2016; 13(11): 3712. CrossRef
Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
AIP Advances.2014;[Epub] CrossRef
Nanocarriers for delivery of platinum anticancer drugs
Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
Advanced Drug Delivery Reviews.2013; 65(13-14): 1667. CrossRef
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
Investigational New Drugs.2012; 30(3): 1224. CrossRef
Cellular interactions of platinum drugs
Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
Inorganica Chimica Acta.2012; 393: 75. CrossRef
What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt, Dan Gibson
Journal of Inorganic Biochemistry.2012; 117: 220. CrossRef
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
European Journal of Surgical Oncology (EJSO).2011; 37(6): 466. CrossRef
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef

12,203 View
114 Download
26 Crossref

A Multi-Center, Phase II Clinical Trial of Padexol™ (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer: Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Young Rok Do, Hong Suk Song, Won Sik Lee, Keon Uk Park, Jin Ho Baek, Jong Gwang Kim; Cancer Res Treat. 2005;37(6):349-353. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.349

Abstract PDF PubReader ePub

Purpose

We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma.

Materials and Methods

39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m² was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m² as an intravenous infusion on day 1, once every 3 weeks.

Results

Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild.

Conclusion

The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by

Effect of the Weekly Administration of Liposome–Paclitaxel Combined with S-1 on Advanced Gastric Cancer
Lei Chen, Qiang Chen, Zhixiang Zhuang, Yusong Zhang, Jialong Tao, Liqin Shen, Xudong Shen, Zhigang Chen, Ji Wang, Minggao Zhu, Hui Wang
Japanese Journal of Clinical Oncology.2014; 44(3): 208. CrossRef
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
Jin Young Kim, Young Rok Do, Keon Uk Park, Jong Gwang Kim, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Hun Mo Ryoo, Sung Hwa Bae, Jin Ho Baek, Hong Suk Song
Cancer Chemotherapy and Pharmacology.2011; 67(3): 527. CrossRef
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Kazuma Okamoto, Eigo Otsuji, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Tetsuro Yamashita, Fumihiro Taniguchi, Hideki Aragane, Hiroshi Nishi, Yoshiki Itokawa, Satoshi Morita, Junichi Sak
Gastric Cancer.2010; 13(3): 149. CrossRef
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Won Sik Lee, Chang-Hak Sohn, Joo Seop Jung, Gab Chul Kim, Ho Young Chung, Wansik Yu
Cancer Chemotherapy and Pharmacology.2009; 64(2): 355. CrossRef
Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
Japanese Journal of Clinical Oncology.2009; 39(4): 237. CrossRef
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Research and Treatment.2007; 39(1): 6. CrossRef
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wan
Cancer Chemotherapy and Pharmacology.2007; 60(6): 863. CrossRef
The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
Cancer Research and Treatment.2006; 38(2): 66. CrossRef

10,323 View
72 Download
8 Crossref

Effect of Combination Chemotherapy with Docetaxel Plus Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: Hee Jung Kang, Min Kyoung Kim, Young Gil Kim, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Sung Hwa Bae, Hun Mo Ryoo; Cancer Res Treat. 2003;35(4):299-303. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.299

Abstract PDF: PURPOSE
This study was conducted to evaluate the efficacy and safety of combination chemotherapy, with docetaxel and cisplatin, as a first line treatment for advanced non-small cell lung cancer.
MATERIALS AND METHODS
Between March 1998 and December 2001, 35 patients with advanced non-small cell lung cancer were enrolled in this study. The patients were treated at 3-week intervals, with one course of a regimen consisting of docetaxel (75 mg/m2 IV for 1 hours) on day 1 and cisplatin (60 mg/m2 IV) on day 2.
RESULTS
The median age of the patients was 60.3 years. Of the 35 patients, 20 and 15 had stage IIIb and stage IV diseases, respectively. A complete response was observed in 1 patient and partial response in 15, with an overall response rate of 46%. The overall median survival duration was 40.3+/-25.2 weeks. The median time to progression and response duration were 21.6+/-5.5 and 15.1+/-5.9 weeks, respectively. The survival duration was statistically significantly longer in the response group (50.6 weeks) than in the non-response group (31.6 weeks) (p<0.05). Of the hematological side effects, grades III and IV leukopenia were observed in 4.8% of patients. Grades III and IV nausea and vomiting were observed in 48.5%, and grades I and II neuropathy in 11.4% of the treated patients. These toxicities were well tolerable and reversible. There were no hypersensitivity reactions.
CONCLUSION
Docetaxel and cisplatin combination chemotherapy is relatively effective and safe in advanced non-small cell lung cancer patients.

4,234 View
34 Download

Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target: Kyung Hee Lee, Myung Soo Hyun, Jae Ryong Kim; Cancer Res Treat. 2003;35(3):207-212. Published online June 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.3.207

Abstract PDF

PURPOSE
Increased expression of the hepatocytes growth factor (HGF) receptor (c-Met) and urokinase type plasminogen activator (uPA) correlate with the development and metastasis of cancers. However, the mechanisms by which HGF/c-Met signaling mediate cancer progression and metastasis are unclear. Therefore, we investigated the roles of HGF/c-Met in tumor progression and metastasis in pancreatic cancer cell lines, L3.6PL and IMIN-PC2. MATERIALS AND METHODS: To see the functional c-Met protein, we were performed immunoprecipitation for functional c-Met protein. And also performed western bolot analysis and gel zymography for the functional uPA protein. To see the inhibition effects of uPAR monoclonal antibody on invasiveness of two pancreatic cancer cell lines, we were carried out standard two chamber invasion assay. RESULTS: At first, we observed the HGF-mediated c-Met phosphorylation and cell growth. c-Met phosphorylation was increased in the HGF-treated cells in a dose dependent manner. HGF resulted in increments of cell growth and ERK phosphorylation. HGF treatment increased the uPA expression and the uPA activity. A monoclonal antibody 3936, specific to uPAR receptor, inhibited HGF- mediated tumor cell invasion in a dose dependent manner.
CONCLUSION
These results suggest that functional c- Met and HGF/c-Met signaling up-regulate the activity of uPA and result in increments of invasion-metastasis in the pancreatic cancer cells.

Citations

Citations to this article as recorded by

PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells
He Xu, Di Wu, Mingming Xiao, Yubin Lei, Yalan Lei, Xianjun Yu, Si Shi
Science Advances.2024;[Epub] CrossRef
Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor
Kyung Hee Lee, Jae-Ryong Kim
Experimental and Molecular Medicine.2009; 41(3): 180. CrossRef
Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells
Kyung Hee Lee, Sang Woon Kim, Jae-Ryong Kim
Journal of Experimental & Clinical Cancer Research.2009;[Epub] CrossRef
Cellular Mechanisms of Hepatocyte Growth Factor-Mediated Urokinase Plasminogen Activator Secretion by MAPK Signaling in Hepatocellular Carcinoma
Kyung Hee Lee, Eun Young Choi, Myung Soo Hyun, Jong Ryul Eun, Byung Ik Jang, Tae Nyeun Kim, Heon Ju Lee, Dong Shik Lee, Sung Su Yun, Hong Jīn Kim, Jung Hye Kim, Jae-Ryong Kim
Tumori Journal.2008; 94(4): 523. CrossRef
Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells
K.H. Lee, E.Y. Choi, M.S. Hyun, B.I. Jang, T.N. Kim, S.W. Kim, S.K. Song, J.H. Kim, J.-R. Kim
European Surgical Research.2007; 39(4): 208. CrossRef
Hepatocyte Growth Factor/c-Met Signaling in Regulating Urokinase Plasminogen Activator in Human Stomach Cancer: A Potential Therapeutic Target for Human Stomach Cancer
Kyung Hee Lee, Eun Young Choi, Myung Soo Hyun, Byung Ik Jang, Tae Nyeun Kim, Sang Woon Kim, Sun Kyo Song, Jung Hye Kim, Jae-Ryong Kim
The Korean Journal of Internal Medicine.2006; 21(1): 20. CrossRef
Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer
Sang Joon Shin, Kyeong Ok Kim, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Keuk Jun Kim, Joon Hyuk Choi, Hong Seok Song
Japanese Journal of Clinical Oncology.2005; 35(6): 342. CrossRef

3,655 View
21 Download
7 Crossref

Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target: Hyun A Oh, Gu Lee, Hee Jung Kang, Yong Gil Kim, Sung Hwa Bae, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Dong Suk Kim; Cancer Res Treat. 2003;35(1):9-15. Published online February 28, 2003; DOI: https://doi.org/10.4143/crt.2003.35.1.9

Abstract PDF

PURPOSE
One of the members of the tyrosine kinase receptor family is the protein product of the c-met proto-oncogene, which is the receptor for hepatocyte growth factor (HGF). HGF is known as a potent mitogen and motogen for many kinds of carcinoma cells, and has been found to simulate the growth and progression of gastric cancer cells through HGF-receptors. In addition, the urokinase-type plasminogen activator (uPA) and receptor (uPAR) also play important roles in the invasion and metastasis. MATERIALS AND METHODS: The expression of c-met protein was investigated using immunohistochemical staining of 50 paraffin embedded gastric cancers, and by measuring the serum uPAR levels, before and after an operation, in gastric cancer patients using an ELISA assay. RESULTS: Of the 50 cases, 32 (64%) expressed the c-met protein. The c-met protein expression was significantly correlated with the TNM staging (p<0.05), but the other prognostic factors were not significant variables. According to a Kaplan-Meier's plot, the one and three year overall survival rates were 94 and 70% in patients not expressing the c-met protein, and 81 and 33% in those that did, and the Survival curves revealed a significantly different prognosis (p=0.04). Elevated serum uPAR levels (> or=3257.8 pg/ml, control+/-mean 2SD) were observed in 9 (34.6%) of 26 gastric cancer patients, but in none of control subjects. Average serum uPAR levels were 2980.8+/-616.2 pg/ml before the operation and 2404.7+/-455.9 pg/ml after, and decreased significantly after surgical resection (p<0.05). The serum uPAR level correlated significantly with lymph node metastasis and vessel invasion (p<0.05) CONCLUSION: The expression of c-met protein, and the level of uPAR, may be prognostic factors in gastric cancer.

Citations

Citations to this article as recorded by

Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer
Lan-Mei Wang, Wei-Wei Zhang, Ying-Yang Qiu, Fang Wang
World Journal of Gastrointestinal Oncology.2024; 16(6): 2781. CrossRef
Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review
Wu-Jie Wei, Ya-Li Hong, Yi Deng, Guan-Liang Wang, Jiang-Tao Qiu, Fang Pan
World Journal of Gastrointestinal Oncology.2024; 16(8): 3397. CrossRef
Human Triosephosphate Isomerase Is a Potential Target in Cancer Due to Commonly Occurring Post-Translational Modifications
Sergio Enríquez-Flores, Ignacio De la Mora-De la Mora, Itzhel García-Torres, Luis A. Flores-López, Yoalli Martínez-Pérez, Gabriel López-Velázquez
Molecules.2023; 28(16): 6163. CrossRef
SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer
Katia De Marco, Martina Lepore Signorile, Elisabetta Di Nicola, Paola Sanese, Candida Fasano, Giovanna Forte, Vittoria Disciglio, Antonino Pantaleo, Greta Varchi, Alberto Del Rio, Valentina Grossi, Cristiano Simone
Cells.2023; 12(20): 2481. CrossRef
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
Han S. Kim, Hong J. Chon, Hyunki Kim, Su‐Jin Shin, Volker Wacheck, Aaron M. Gruver, Jong S. Kim, Sun Y. Rha, Hyun C. Chung
Journal of Surgical Oncology.2018; 117(8): 1679. CrossRef
Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells
Kyung Hee Lee, Jae-Ryong Kim
Clinical & Experimental Metastasis.2009; 26(7): 685. CrossRef
Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells
K.H. Lee, E.Y. Choi, M.S. Hyun, B.I. Jang, T.N. Kim, S.W. Kim, S.K. Song, J.H. Kim, J.-R. Kim
European Surgical Research.2007; 39(4): 208. CrossRef

4,547 View
29 Download
7 Crossref

C-erbB-2 Protein Expression and Correlation in Sera and Tumors of Non-Small Cell Lung Cancer Patients: Hun Mo Ryoo, Sang Yeop Lee, Kyung Hee Lee, Myung Soo Hyun, Mi Jin Kim; J Korean Cancer Assoc. 2000;32(6):1100-1108.

Abstract PDF: PURPOSE
We have examined the expression of c-erbB-2 oncogene in sera and tissues of non-small cell lung cancer patients.
MATERIALS AND METHODS
Serum levels of c-erbB-2 protein were measured by an enzyme im munoassay in 55 patients with non-small cell lung cancer. Sera from patients with surgical therapy were evaluated again after surgery. Immunohistochemical staining was performed in 47 of these tumors.
RESULTS
Elevated levels (> or =45 U/mL, control mean 2SD) were observed in 15% of 55 non-small cell lung cancer patients, as compared with none of control subjects (p<0.05). The incidence of elevated level was higher in the adenocarcinoma than squamous cell carcinoma (22% vs 4%, p<0.01). The serum levels of c-erbB-2 protein decreased significantly after surgical tumor ablation (p<0.01). Tissue overexpression was obtained in 23/47 cases (49%). The incidence of c-erbB-2 overexpression was higher in the adenocarcinoma (73% vs 29%, p<0.005). No relationship was found between c-erbB-2 protein expression in serum and tumor tissue and clinicopathologic feature. Elevated serum c-erbB-2 levels predicted tissue overexpression with sensitivity 30% and specificity 96%. There was relationship between serum level and expression in tumor tissue of c-erbB-2 protein.
CONCLUSION
Serum and tissue levels of c-erbB-2 correlate in patients with non-small cell carcinoma. Serum c-erbB-2 protein may be a useful indicator of tumor burden in patients with non-small cell lung cancer.

2,856 View
17 Download

A Case of Malignant Chondroid Syringoma with Lung Metastasis: Duck Hee Kim, Chan Woo Lee, Kyung Hee Lee, Myung Soo Hyun; J Korean Cancer Assoc. 1997;29(6):1119-1119.

Abstract PDF: Malignant chondroid syringoma, previously called "mixed tumor of the skin of the salivary gland type"is a fairly uncommon type of sweat gland tumor. Malignant chondroid syringoma frequently arises from the trunk and extremities, whereas the benign tumor is common to the head region. The present case occurred in a female. The malignant nature of the tumor was evident from repeated recurrences after excision of the mass and histopathological study. Lack of response to radiotherapy and chemotherapy led to widespread metastasis. We report a case of malignant chondroid syringoma with lung metastasis in a 39-year-old female patient and response to chemotherapy. We also reviewed the literatures of malignant chondroid syringoma.

3,182 View
37 Download

COP - BLAM Combination Chemotherapy for the Treatment of Intermediate and High Grade Non - Hodgkin's Lymphoma: Jae Seong Lee, Jang Su Suh, Myung Soo Hyun; J Korean Cancer Assoc. 1994;26(5):806-815.

Abstract PDF: Between March 1987 and December 1993, 45 patients with intermediate and high grade non- Hodgkin's lymphoma were treated with a COP-BLAM(cyclophosphamide, oncovin, prednisone, procarbazine, bleomycin, adriamycin) combination chemotherapy. The median age was 49 years(range 16-76). 29 patiets were male and 16 patients were female. The common histologic types were diffuse large cell type(68.9%), diffuse small cleaved cell type(13.3%), and diffuse mixed small and large cell type(11.1%). The proportion of patients with 'B symptom, bulky mass, and LDH>550 IU/L at diagnosis was 42.4%, 6.7%, 33.3%, respectively. The rate of complete remission was 71.1%, and overall response rate was 93.3%. 2 year survi- val rate was 76.8/, but the median survival time was not reached right now(the median follow up time: l7 months). Age, serum LDH level at diagnosis, lower performance scale, stage, and cell type were significantly associated with CR rate. Stage, serum LDH level at diagnosis, and bulky mass were significantly associated with 2 year survival rate. Overall toxicity was acceptible without any treatment related deaths.

2,529 View
15 Download

Alternating Combination Chemotherapy of CAV with EP in Small Cell Lung Gancer and Effect of Concurrent Thoracic Radiotherapy in Limited Stage: Kyung Hee Lee, Jin Jong Jeon, Byung Hoon Kim, Eun Jeong Lee, Jun Young Do, Jin Hong Chung, Kwan Ho Lee, Myung Soo Hyun, Bong Sub Shim, Hyun Woo Lee, Hyun Cheol chung; J Korean Cancer Assoc. 1996;28(1):104-113.

Abstract PDF: In order to assess the efficacy of alternating schedule chemotherapy on the outcome of patients with small cell lung cancer and effect of concurrent thoracic radiotherapy in limited disease, fifty five eligible patients with SCLC were treated with chemotherapy consisting of cyclophosphamide, adriamycin and vincristine(CAV) alternating with etoposide and cisplatin(EP). Thoracic radiotherapy was administered to the patients with limited stage disease Overall response rate was 64% with 20% of complete response. The response rate was 78%(CR 39%,PR 39%)in the patients with limited stage disease, and 53%(CR 6%, PR 47%)in those with extensive stage disease. With median follow-up period of 14 months (341+), the median survivals in patients of limited stage and extended disease were 15 months and 10 month, respectively (p<0.02) and median survivals in patients with CR, PR, and SD+PD were 20, 11.3, 8.5months, respectively(p<0.01) In patients with limited stage patients with or without concurrent use of thoracic radiotherapy, the response rates were 82%(CR 42%, PR 41%) and 67%(CR 33%, PR 34%) and median survivals were 15.8 months and 11.8 months, respectively.There were no life threatening side effects. This results suggest that alternating chemotherapy with CAV and EP may be useful as a treatement strategy in small cell lung cancer and concurrent use of thoracic radiotherapy in limited stage patients improve survival, but it was not significant statistically.

2,967 View
14 Download

First
Prev
Page of 1
Next
Last

Search